Tenuto v. Lederle Laboratories, Division of American Cyanamid Co.

687 N.E.2d 1300, 90 N.Y.2d 606, 665 N.Y.S.2d 17, 1997 N.Y. LEXIS 3219
CourtNew York Court of Appeals
DecidedOctober 23, 1997
StatusPublished
Cited by55 cases

This text of 687 N.E.2d 1300 (Tenuto v. Lederle Laboratories, Division of American Cyanamid Co.) is published on Counsel Stack Legal Research, covering New York Court of Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Tenuto v. Lederle Laboratories, Division of American Cyanamid Co., 687 N.E.2d 1300, 90 N.Y.2d 606, 665 N.Y.S.2d 17, 1997 N.Y. LEXIS 3219 (N.Y. 1997).

Opinion

OPINION OF THE COURT

Levine, J.

Plaintiffs appeal, pursuant to leave granted by this Court, from an order of the Appellate Division which (1) reversed, on the law, an order of Supreme Court denying the motion for summary judgment of defendant (now deceased) Leroy L. Schwartz, M.D., dismissing the cross claim of defendant Lederle Laboratories; (2) granted that motion; and (3) dismissed the cross claim. The appeal from this order, which is final as to defendant Schwartz under the principle of party finality, brings up for review a prior nonfinal order of the Appellate Division, which affirmed an order of Supreme Court granting defendant Schwartz’s motion to dismiss plaintiffs’ complaint against him pursuant to CPLR 3211 (a) (7). Defendant Lederle Laboratories has not appealed the dismissal of its cross claim against defendant Schwartz. As set forth in the complaint, bill of particulars and other submissions in opposition to defendant Schwartz’s motion to dismiss, plaintiffs’ allegations, which we must accépt *610 as true and accord every possible favorable inference therefrom (s ee, Leon v Martinez, 84 NY2d 83, 87-88), would establish the following facts.

In May 1979, based upon advice from Dr. Schwartz, plaintiffs Dominick and Elizabeth Tenuto presented their five-month-old daughter to him for a second dosage of an oral poliomyelitis vaccine manufactured by defendant Lederle Laboratories, trade named "Orimune.” Orimune and other similar oral vaccines consist of three live but weakened strains of the polio virus. Although the pharmaceutical manufacturer had rendered the viruses incapable of producing paralytic disease in a person receiving the vaccine, they cause the production of antibodies which will resist an attack by a wild or virulent polio virus. Typically, oral polio vaccines are administered to infants during their first year of life.

While an oral polio vaccine of live viruses has significant clinical advantages over the alternative, original method of polio vaccination (discovered by Dr. Jonas Salk) involving injection of a vaccine containing killed or inactivated polio virus strains, oral vaccines carry certain unique risks. Notably, as is described in detail in Plummer v Lederle Labs. (819 F2d 349, 351-353, cert denied 484 US 898), on a rare but statistically predictable basis, the live viruses lodging in the infant recipient’s gastrointestinal tract may grow and revert to virulent form. When those wild viruses are later discharged from the infant’s bowel in excretion or from the mouth in saliva, contact with the feces or saliva by the child’s adult caretakers may result in infection and, in the case of vulnerable adults (i.e., unvaccinated or where immunization has weakened over time), may result in paralytic polio.

The foregoing risk of parental "contact” polio derived from oral vaccination of a child, has been known since 1961. By the 1970s, United States governmental health officials were recommending that consumers be advised of the risks as well as benefits of oral polio vaccines. Accordingly, as of 1977, defendant Lederle Laboratories included in its Orimune package insert some description of the risks and the recommendation, also reproduced in the Physician’s Desk Reference, that such danger be communicated to the parents when an infant is to be orally vaccinated, so that suitable precautions can be taken. *611 The insert also warned against injection of the vaccine directly into the bloodstream. *

Plaintiffs allege that Dr. Schwartz, although informed that Mr. Tenuto was about to undergo elective surgery, never inquired as to whether he had previously been vaccinated against polio nor advised plaintiffs of the risk of incurring contact polio and of the precautions necessary to prevent exposure, particularly in light of the surgical wound which would result from the immediately impending surgery of Mr. Tenuto.

As a consequence, in caring for his daughter following his operation, Mr. Tenuto was exposed to virulent polio viruses. Within 30 days of the infant’s vaccination, Mr. Tenuto began to exhibit the symptoms of paralytic poliomyelitis and was then hospitalized and diagnosed as afflicted with that disease. His polio has rendered him a permanent paraplegic. Plaintiffs submitted, in camera, an affidavit from a qualified scientific expert that he was infected as a result of the oral vaccine administered to his daughter by Dr. Schwartz. A second affidavit, from a medical expert, expressed an opinion that, at the time the vaccine was administered to plaintiffs’ infant daughter, the standard of medical care required advising parents of the risk of contact polio and that appropriate precautions should be taken.

The Tenutos subsequently brought this action against Dr. Schwartz and Lederle Laboratories, based on Mr. Tenuto’s personal injury and his wife’s derivative losses. Dr. Schwartz moved to dismiss the claims against him on the ground that they were based entirely on a failure to obtain the statutory informed consent mandated by Public Health Law § 2805-d— claims which would not lie because the Tenutos were not his patients. Supreme Court agreed and granted Dr. Schwartz’s motion. The Appellate Division affirmed for the same reason (207 AD2d 541).

We now reverse. The courts below too restrictively read plaintiffs’ allegations contained in the complaint, bill of particulars and other papers. A statutory cause of action pursuant to Public Health Law § 2805-d was not the only cognizable legal theory upon which plaintiffs’ allegations rested (see, Leon v Martinez, supra, 84 NY2d, at 87-88). Both expressly and *612 by fair implication, plaintiffs have alleged that Dr. Schwartz owed them a duty of care based on common-law principles of ordinary negligence and malpractice. That duty, claimed by plaintiffs, consisted among other things, of complying with the recommendations of the vaccine manufacturer to warn plaintiffs of their personal health risks from the vaccination of their infant daughter, to assess the particular vulnerabilities of plaintiffs to those risks and to advise plaintiffs of precautions to avoid or minimize them. We have concluded, under the circumstances of this case, that a duty of reasonable care extended to plaintiffs despite the absence of a direct doctor/ patient treatment relationship between them and Dr. Schwartz.

"The question of whether a member or group of society owes a duty of care to reasonably avoid injury to another is of course a question of law for the courts” (Purdy v Public Adm’r, 72 NY2d 1, 8, rearg denied 72 NY2d 953; see also, Eiseman v State of New York, 70 NY2d 175, 187; De Angelis v Lutheran Med. Ctr., 58 NY2d 1053, 1055). Courts resolve legal duty questions by resort to common concepts of morality, logic and consideration of the social consequences of imposing the duty (see, Eiseman v State of New York, supra, at 187).

In Eiseman, we recognized that, under appropriate circumstances, common morality, logic and social policy could permit a limited extension of the duty of care of a physician beyond the immediate patient under treatment.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Kleiner v. New York City Health & Hosps. Corp.
2025 NY Slip Op 51558(U) (New York Supreme Court, New York County, 2025)
Cardenas v. Rochester Regional Health
2021 NY Slip Op 01641 (Appellate Division of the Supreme Court of New York, 2021)
John v. De Vivo
2020 NY Slip Op 542 (Appellate Division of the Supreme Court of New York, 2020)
Santoro v. Poughkeepsie Crossings, LLC
2019 NY Slip Op 8883 (Appellate Division of the Supreme Court of New York, 2019)
Melio v. John T. Mather Mem. Hosp.
2018 NY Slip Op 6524 (Appellate Division of the Supreme Court of New York, 2018)
Kingsley v. Price
2018 NY Slip Op 5088 (Appellate Division of the Supreme Court of New York, 2018)
Vega v. Crane
2018 NY Slip Op 3262 (Appellate Division of the Supreme Court of New York, 2018)
Ferguson v. Laffer
2017 NY Slip Op 2967 (Appellate Division of the Supreme Court of New York, 2017)
Alves v. Santos
55 Misc. 3d 799 (New York Supreme Court, 2017)
Vega v. Crane
55 Misc. 3d 811 (New York Supreme Court, 2017)
On v. BKO Express LLC
2017 NY Slip Op 281 (Appellate Division of the Supreme Court of New York, 2017)
Torres v. Faxton St. Lukes Healthcare
227 F. Supp. 3d 216 (N.D. New York, 2017)
Joseph v. Dartmouth-Hitchcock Clinic
Vermont Superior Court, 2016
Davis v. South Nassau Communities Hospital
46 N.E.3d 614 (New York Court of Appeals, 2015)
Malone v. County of Suffolk
128 A.D.3d 651 (Appellate Division of the Supreme Court of New York, 2015)
Judge Rotenberg Educational Center Inc. v. Blass
882 F. Supp. 2d 371 (E.D. New York, 2012)
Fox v. Marshall
88 A.D.3d 131 (Appellate Division of the Supreme Court of New York, 2011)
Klein v. Bialer
72 A.D.3d 744 (Appellate Division of the Supreme Court of New York, 2010)
Tenuto v. Lederle Laboratories
27 Misc. 3d 506 (New York Supreme Court, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
687 N.E.2d 1300, 90 N.Y.2d 606, 665 N.Y.S.2d 17, 1997 N.Y. LEXIS 3219, Counsel Stack Legal Research, https://law.counselstack.com/opinion/tenuto-v-lederle-laboratories-division-of-american-cyanamid-co-ny-1997.